Transaction positions Jaguar to advance the Laminar program and its differentiated approach to left atrial appendage closure for patients with non-valvular atrial fibrillation

该交易使Jaguar公司能够推进Laminar项目，并以其差异化方法为患有非瓣膜性心房颤动的患者提供左心耳封堵治疗。

SANTA ROSA, Calif.

加利福尼亚州圣罗莎

,

，

Sept. 11, 2026

2026年9月11日

/PRNewswire/ -- Jaguar LAA, Inc. ('Jaguar'), a privately held medical device company, today announced the acquisition of assets related to the Laminar program, focused on addressing the left atrial appendage ('LAA') in patients with non-valvular atrial fibrillation ('AFib'), from Johnson & Johnson..

/美通社/ -- 私营医疗器械公司Jaguar LAA, Inc.（“Jaguar”）今日宣布，从强生公司收购与Laminar项目相关的资产，该项目专注于解决非瓣膜性心房颤动（“AFib”）患者的左心耳（“LAA”）问题。

The transaction brings key Laminar program assets together with members of the team responsible for their development in a newly formed, independent company. Jaguar intends to build on the clinical and development work completed to date and advance the program through its next stages of development and regulatory review..

此次交易将Laminar项目的关键资产与其开发团队成员整合至一家新成立的独立公司中。捷豹路虎旨在依托迄今已完成的临床与开发工作，推动该项目进入后续的开发阶段并接受监管审查。

AFib is a common heart rhythm disorder associated with an increased risk of stroke. In patients with non-valvular AFib, the LAA is an important source of thrombus formation and has long been an area of clinical focus in cardiology and electrophysiology. The Laminar program uses a catheter-based approach and rotational motion to close and eliminate the LAA while leaving minimal device exposure within the left atrium..

房颤是一种常见的心律失常，与卒中风险增加相关。在非瓣膜性房颤患者中，左心耳（LAA）是血栓形成的重要来源，长期以来一直是心脏病学和电生理学领域的临床关注重点。Laminar 项目采用基于导管的方法和旋转运动来封闭并消除左心耳，同时在左心房内留下的器械暴露部分极少。

'We believe the Laminar technology offers a differentiated approach to LAA closure, particularly through its ability to leave minimal device exposure within the left atrium,' said Jason Rogers, Chief Medical Officer of Jaguar. 'We are excited to continue the work behind the program and explore its potential to provide an important new treatment option for patients with atrial fibrillation.'.

“我们相信，Laminar技术为左心耳（LAA）封堵提供了一种差异化的方法，尤其是其能够在左心房内留下极少的器械暴露部分。”Jaguar公司首席医疗官Jason Rogers表示。“我们很高兴能继续推进该项目，并探索其为房颤患者提供一种重要的新治疗选择的潜力。”

Jaguar was formed in partnership with Santé Ventures and members of the Laminar management team. Santé, alongside management and other investors, led the formation and financing of Jaguar and the transaction with Johnson & Johnson. Financial terms were not disclosed.

Jaguar 是与 Santé Ventures 以及 Laminar 管理团队成员合作成立的。Santé 与管理层及其他投资者共同主导了 Jaguar 的成立、融资以及与强生公司的交易。财务条款未予披露。

About Jaguar LAA, Inc.

关于捷豹LAA公司

Jaguar LAA, Inc. is a medical device company focused on developing catheter-based technologies for left atrial appendage closure intended to reduce the risk of stroke in patients with non-valvular atrial fibrillation. Jaguar is headquartered in Santa Rosa, California.

Jaguar LAA, Inc. 是一家医疗器械公司，专注于开发用于左心耳封堵的导管技术，旨在降低非瓣膜性心房颤动患者的卒中风险。Jaguar 总部位于加利福尼亚州圣罗莎。

About Santé Ventures

关于 Santé Ventures

Founded in 2006, Santé Ventures is a healthcare and life sciences investment firm with more than $1 billion in capital under management. The firm invests in early-stage medical technologies, biotechnology, and digitally enabled healthcare services, with offices in Austin, Texas, and Boston, Massachusetts.

Santé Ventures 成立于2006年，是一家医疗保健和生命科学投资公司，管理资本超过10亿美元。该公司专注于投资早期阶段的医疗技术、生物技术和数字化赋能的医疗服务，在德克萨斯州奥斯汀和马萨诸塞州波士顿设有办公室。

For more information, visit .

更多信息，请访问。

www.sante.com

www.sante.com

.

。

Media Contact

媒体联系人

Brooke Jones

布鲁克·琼斯

[email protected]

[email protected]

SOURCE Santé Ventures

来源：Santé Ventures

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示